Theravance Biopharma (TBPH) Change in Accured Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Change in Accured Expenses data on file, last reported at -$4.9 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 221.47% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was $656000.0, a 80.42% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, up 173.09% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.9 million, down from -$1.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for TBPH reached as high as $17.2 million in Q4 2022 and fell as low as -$10.3 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$454764.7 across 5 years, with a median of -$791000.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 2740.95% in 2022 and fell as far as 665.25% in 2022.
• Year by year, Change in Accured Expenses stood at $17.2 million in 2022, then tumbled by 102.54% to -$438000.0 in 2023, then soared by 782.88% to $3.0 million in 2024, then slumped by 142.63% to -$1.3 million in 2025, then slumped by 281.73% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.9 million in Q1 2026, -$1.3 million in Q4 2025, and $3.6 million in Q3 2025.